Off-Label Communication: Industry Opposes Exclusion Of Phase II Data From US FDA’s Guidance

 
• By Brenda Sandburg
Off label use
The pharma industry criticized guidance on communication of scientific information about a product's unapproved uses. • Source: Shutterstock

More from Marketing & Advertising

More from Compliance